STAT3 and osteosarcoma: Research has confirmed that miR-506-3p can counteract chemoresistance to doxorubicin in U-2OS osteosarcoma cells by inhibiting JAK2 phosphorylation and lowering total STAT3 protein levels in drug-resistant cells.